Revolution Medicines, Inc. (RVMD)
RVMD Stock Price Chart
Explore Revolution Medicines, Inc. interactive price chart. Choose custom timeframes to analyze RVMD price movements and trends.
RVMD Company Profile
Discover essential business fundamentals and corporate details for Revolution Medicines, Inc. (RVMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Feb 2020
Employees
616.00
Website
https://www.revmed.comCEO
Mark A. Goldsmith
Description
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
RVMD Financial Timeline
Browse a chronological timeline of Revolution Medicines, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$1.96, while revenue estimate is $17.78m.
Earnings released on 6 May 2026
EPS came in at -$2.29 falling short of the estimated -$1.84 by -24.46%.
Earnings released on 25 Feb 2026
EPS came in at -$1.86 falling short of the estimated -$1.58 by -17.72%.
Earnings released on 5 Nov 2025
EPS came in at -$1.61 falling short of the estimated -$1.42 by -13.38%.
Earnings released on 6 Aug 2025
EPS came in at -$1.31 falling short of the estimated -$0.94 by -39.36%.
Earnings released on 7 May 2025
EPS came in at -$1.13 falling short of the estimated -$1.12 by -0.89%.
Earnings released on 26 Feb 2025
EPS came in at -$1.12 falling short of the estimated -$1.01 by -10.89%, while revenue for the quarter reached $261.59m , beating expectations by +75.47k%.
Earnings released on 6 Nov 2024
EPS came in at -$0.94 falling short of the estimated -$0.89 by -5.24%.
Earnings released on 7 Aug 2024
EPS came in at -$0.81 falling short of the estimated -$0.77 by -5.19%.
Earnings released on 8 May 2024
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.21%.
Earnings released on 26 Feb 2024
EPS came in at -$1.14 falling short of the estimated -$0.86 by -32.56%, while revenue for the quarter reached $742.00k , missing expectations by -31.93%.
Earnings released on 6 Nov 2023
EPS came in at -$0.99 surpassing the estimated -$1.01 by +1.98%.
Earnings released on 8 Aug 2023
EPS came in at -$0.92 falling short of the estimated -$0.83 by -10.84%, while revenue for the quarter reached $3.82m , beating expectations by +145.13%.
Earnings released on 8 May 2023
EPS came in at -$0.72 surpassing the estimated -$0.84 by +14.29%, while revenue for the quarter reached $7.01m , beating expectations by +138.57%.
Earnings released on 27 Feb 2023
EPS came in at -$0.63 surpassing the estimated -$0.84 by +25.00%, while revenue for the quarter reached $15.33m , beating expectations by +96.47%.
Earnings released on 7 Nov 2022
EPS came in at -$0.87 matching the estimated -$0.87, while revenue for the quarter reached $3.36m , missing expectations by -47.04%.
Earnings released on 9 Aug 2022
EPS came in at -$0.82 surpassing the estimated -$0.87 by +5.75%, while revenue for the quarter reached $9.12m , beating expectations by +29.89%.
Earnings released on 9 May 2022
EPS came in at -$0.78 surpassing the estimated -$0.82 by +4.88%, while revenue for the quarter reached $7.58m , missing expectations by -11.71%.
Earnings released on 28 Feb 2022
EPS came in at -$0.71 falling short of the estimated -$0.65 by -9.23%, while revenue for the quarter reached $9.46m , beating expectations by +5.23%.
Earnings released on 10 Nov 2021
EPS came in at -$0.72 falling short of the estimated -$0.62 by -16.13%, while revenue for the quarter reached $1.10m , beating expectations by +19.23%.
Earnings released on 11 Aug 2021
EPS came in at -$0.60 falling short of the estimated -$0.55 by -9.09%, while revenue for the quarter reached $8.70m , meeting expectations.
RVMD Stock Performance
Access detailed RVMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
